AGM statement and H1 trading update

AI SummaryClose X

Fusion Antibodies PLC announced unaudited revenues for the first half of the financial year ending March 31, 2026, were approximately £838k, down from £1.2m in the prior year's first half but up from £755k in the second half of last year. The unaudited gross margin for the period was 30%, an increase from 22% in the prior year. Cash as of September 30, 2025, was £251k, tracking in line with management's expectations. The company also highlighted the grant of their US patent covering the OptiMAL® library design and method. They anticipate a stronger performance in the second half of the year.

Disclaimer*

UK 100

Latest directors dealings